Clinical trial · Observational
CAR-T Treatment in Pediatric and Adult Acute Lymphoblastic Leukemia
Observational Retrospective and Prospective Multicentric Study on CAR-T Cell for the Treatment of Pediatric and Adult B-cell Acute Lymphoblastic Leukemia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to evaluate the efficacy of the treatment with approved CAR-T cells in Italy in pediatric and adult patients with acute B-cell lymphoblastic leukemia. The main question it aims to answer is: which is the overall response rate in pediatric and adult patients with acute B-cell lymphoblastic leukemia treated with approved CAR-T cells? Data will be extracted from patients medical records.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
| B-Cell Acute Lymphoblastic Leukaemia | B Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Patients with acute lymphoblastic leukemia treated with CAR-T cells
- description
- Pediatric and adult patients with B-cell acute lymhoblastic leukemia treated with approved CAR-T cells in Italy
Primary outcomes (1)
- measure
- Overall response
- timeFrame
- 12 months
- description
- Rate of patients that obatain a response
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Diagnosis of ALL R/R CD19+ 2. Patients are pediatric (all patients up to the age of 18) adult (all comers older than 18) 3. Prescribed treatment with Tisagenlecleucel or Brexucabtagene autoleucel as per approved AIFA criteria, or obecabtagene autoleucel - as well as other products - when available 4. Provided consent (or did not opposed) for collection and use of patient data per local regulations Exclusion Criteria: None \-
References
Publications (0)
Data not yet available